Cat. No.: HY-101255

ODQ

11 Cited Publications

Avis client

Based on 11 publication(s) in Google Scholar

ODQ is a potent and selective soluble guanylyl cyclase (sGC, nitric oxide-activated enzyme) inhibitor. ODQ enhances the pro-apoptotic effects of Cisplatin in human mesothelioma cells.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.75%
CAS No.: 41443-28-1
Formule: C₉H₅N₃O₂
Masse moléculaire:187.16

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

ODQ Chemical Structure

CAS No.: 41443-28-1

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- In Vitro
- In Vivo
- Essai clinique
Chemical Information
Publications (11)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

ODQ is a potent and selective soluble guanylyl cyclase (sGC, nitric oxide-activated enzyme) inhibitor. ODQ enhances the pro-apoptotic effects of Cisplatin in human mesothelioma cells^[1].

In Vitro

At 30 and 50 μM, ODQ causes significant induction of apoptosis in the NCI-H2452 cells, elevating apoptotic levels by 12 fold and 15 fold, respectively. At 10μM, a concentration below the threshold for induction of apoptosis by ODQ, ODQ in combination with Cisplatin enhanced (in fact, doubled) the pro-apoptotic effects of Cisplatin at 1 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

ODQ (2 mg/kg; i.p.) reduces the multiple organ injury and dysfunction caused by wall fragments of Gram-positive or Gram-negative bacteria in the anesthetized rat^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Anesthetized, male Wistar rats^[2]
Dosage:

2 mg/kg
Administration:

I.p.
Result:

Attenuated the renal dysfunction, lung injury, and hepatocellular injury caused by lipoteichoic acid/peptidoglycan or lipopolysaccharide.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 41443-28-1
Appearance Solid
Masse moléculaire 187.16
Formule C₉H₅N₃O₂
Color Off-white to yellow
SMILES

O=C1ON=C2N1C3=C(C=CC=C3)N=C2
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (11)

All In Vivo Efficacy StudyWBFlow Cytometry

Sort by:

Journal Impact Factor

Nature

Rescuing dendritic cell interstitial motility sustains antitumour immunity. [Abstract]

2025 Sep;645(8079):244-253. PMID: 40562926
EMBO J

Pericyte signaling via soluble guanylate cyclase shapes the vascular niche and microenvironment of tumors. [Abstract]

2024 Apr;43(8):1519-1544. PMID: 38528180

ODQ purchased from MedChemExpress. Usage Cited in: EMBO J. 2024 Apr;43(8):1519-1544. [Abstract]

Schematic depiction of the experimental design. Wild-type mice were subcutaneously inoculated with LLC cells at 8 weeks of age, and then received oral administration of 2.5 mg/kg Fruquintinib or corresponding vehicle and intraperitoneal injection of 6 mg/kg ODQ or corresponding vehicle, both starting from day 6 post-tumor inoculation, with tumor analysis at day 14 post inoculation.

ODQ purchased from MedChemExpress. Usage Cited in: EMBO J. 2024 Apr;43(8):1519-1544. [Abstract]

Plot depicting the growth curves of LLC tumors in wild-type mice with Fruquintinib or ODQ (6 mg/kg, ip) treatment.

ODQ purchased from MedChemExpress. Usage Cited in: EMBO J. 2024 Apr;43(8):1519-1544. [Abstract]

Macroscope images of LLC tumors isolated from wild-type mice with Fruquintinib or ODQ (6 mg/kg, ip) treatment. Scale bars, 10 mm.

ODQ purchased from MedChemExpress. Usage Cited in: EMBO J. 2024 Apr;43(8):1519-1544. [Abstract]

Plot showing the CD31-positive area, pericyte coverage, and vessel diameter of wild-type mice with Fruquintinib or ODQ (6 mg/kg, ip) treatment.
Int J Mol Med

Naringenin modulates the NO‑cGMP‑PKG signaling pathway by binding to AKT to enhance osteogenic differentiation in hPDLSCs. [Abstract]

2024 Aug;54(2):67. PMID: 38940332

ODQ purchased from MedChemExpress. Usage Cited in: Int J Mol Med. 2024 Aug;54(2):67. [Abstract]

Upon addition of ODQ (an sGC inhibitor), the NAR + ODQ (20 μM) group exhibited decreased expression of the osteogenesis-related factors, RUNX2 and OPN, at both the gene and protein levels.
J Ethnopharmacol

Exploring the molecular mechanism of Shenling baizhu formula in the treatment of ulcerative colitis via the cGMP-PKG signaling pathway. [Abstract]

2026 Jun 12:364:121498. PMID: 41796620
Pharmaceuticals (Basel)

In Vivo Antihypertensive and Ex Vivo Vasodilatory Studies of Taxifolin. [Abstract]

2025 Sep 21;18(9):1420. PMID: 41011287
Eur J Pharmacol

HEC95468, a novel soluble guanylate cyclase stimulator, shows protection in the Dahl model of cardiorenal disorder. [Abstract]

2025 Nov 5:1006:178190. PMID: 40998191
J Biol Chem

Nitric oxide mediates ET-1-induced-inhibition of NPPB-sensitive Cl- currents in the early distal convoluted tubule of the mouse kidney. [Abstract]

2026 Jan 23;302(3):111202. PMID: 41581878
Acad Radiol

Ultrasound-Stimulated Microbubbles Cavitation Combined with Nitric Oxide Signaling Pathway to Alleviate Tumor Hypoperfusion and Hypoxia in MC38 Tumor Model. [Abstract]

2025 Jul;32(7):4121-4133. PMID: 40234163
J Virol

Seneca Valley virus 3C protease targets the Nrf2/HO-1 pathway to antagonize its antiviral activity. [Abstract]

2026 Feb 17;100(2):e0165625. PMID: 41489372
Microbiol Spectr

Heme oxygenase-1 is an equid alphaherpesvirus 8 replication restriction host protein and suppresses viral replication via the PKCβ/ERK1/ERK2 and NO/cGMP/PKG pathway. [Abstract]

2024 Apr 2;12(4):e0322023. PMID: 38441979
In Vitro Model

2025 Oct 28.

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (534.31 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.3431 mL

26.7154 mL

53.4308 mL

5 mM

1.0686 mL

5.3431 mL

10.6862 mL

10 mM

0.5343 mL

2.6715 mL

5.3431 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 5 mg/mL (26.72 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (281 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Ronald Fiscus, et al. ODQ, an inhibitor of soluble guanylyl cyclase (nitric oxide-activated enzyme), enhances the pro-apoptotic effects of cisplatin in human mesothelioma cells. Cancer Res May 1 2007 (67) (9 Supplement) LB-43.

[2]. Zacharowski K, et al. The selective guanylate cyclase inhibitor ODQ reduces multiple organ injury in rodent models of Gram-positive and Gram-negative shock. Crit Care Med. 2001;29(8):1599-1608. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	5.3431 mL	26.7154 mL	53.4308 mL	133.5770 mL
	5 mM	1.0686 mL	5.3431 mL	10.6862 mL	26.7154 mL
	10 mM	0.5343 mL	2.6715 mL	5.3431 mL	13.3577 mL
	15 mM	0.3562 mL	1.7810 mL	3.5621 mL	8.9051 mL
	20 mM	0.2672 mL	1.3358 mL	2.6715 mL	6.6788 mL
	25 mM	0.2137 mL	1.0686 mL	2.1372 mL	5.3431 mL
	30 mM	0.1781 mL	0.8905 mL	1.7810 mL	4.4526 mL
	40 mM	0.1336 mL	0.6679 mL	1.3358 mL	3.3394 mL
	50 mM	0.1069 mL	0.5343 mL	1.0686 mL	2.6715 mL
	60 mM	0.0891 mL	0.4453 mL	0.8905 mL	2.2263 mL
	80 mM	0.0668 mL	0.3339 mL	0.6679 mL	1.6697 mL
	100 mM	0.0534 mL	0.2672 mL	0.5343 mL	1.3358 mL

Keywords

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

ODQ

Apoptosis Compound Library

GPCR/G Protein Compound Library

Anti-Cancer Compound Library

Targeted Diversity Library

Human Metabolite Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) ODQ

Activité biologique

Chemical Information

Publications (11)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

ODQ

Apoptosis Compound Library

GPCR/G Protein Compound Library

Anti-Cancer Compound Library

Targeted Diversity Library

Human Metabolite Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) ODQ

Activité biologique

Chemical Information

Publications (11)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

ODQ Related Classifications

HY-101255 Related Classifications